Hemophilia A – Unmet Need – Unmet Need – Severe Hemophilia A Without Inhibitors (US/EU)
The primary goal of hemophilia A treatment is to prevent bleeding. Hemophilia A patients are a heterogeneous cohort; the tendency to bleed is highly individual. Currently available treatments including FVIII replacement therapies (e.g., Takeda’s Advate, Sanofi’s Eloctate) and Roche’s Hemlibra have helped significantly to reduce bleeding rates; nevertheless, breakthrough bleeds remain almost inevitable for severe hemophiliacs. Although full correction of coagulation is not necessary to stop bleeding, having a greater correction than is achievable using the current prophylactic treatments remains an unmet need, alongside an improved QOL and reduced dosing burden.
QUESTIONS ANSWERED
- What are the key treatment drivers and goals within severe hemophilia A? How do the current therapies perform on these goals?
- Which unmet needs are viewed by physicians as most important? Is further reduction in ABR the ultimate goal?
- Are the impact on QOL and dosing burden viewed as important attributes of emerging therapies?·
- Based on a conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and prices are acceptable to U.S. and European hematologists for a hypothetical hemophilia drug?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European hematologists fielded in March 2021
Key companies: Bayer, Novo Nordisk, Roche, Sanofi, Takeda
Key drugs: Advate, Eloctate, Esperoct, Hemlibra, plasma-derived FVIII
Table of contents
- Hemophilia A - Unmet Need - Unmet Need - Severe Hemophilia A Without Inhibitors (US/EU)
- Unmet Need - Hemophilia A - Severe Without Inhibitors - TPP Simulator - May 2021
- Executive Summary
- Introduction
- Treatment Drivers and Goals
- Key Findings: Attribute Importance
- Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Hematologists' Prescribing Decisions in Severe Hemophilia A Without Inhibitors
- Importance of Efficacy Attributes to Prescribing Decisions in Severe Hemophilia A Without Inhibitors: United States
- Importance of Efficacy Attributes to Prescribing Decisions in Severe Hemophilia A Without Inhibitors: Europe
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Severe Hemophilia A Without Inhibitors: United States
- Importance of Safety and Tolerability Attributes to Prescribing Decisions in Severe Hemophilia A Without Inhibitors: Europe
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Severe Hemophilia A Without Inhibitors: United States
- Importance of Convenience of Administration Attributes to Prescribing Decisions in Severe Hemophilia A Without Inhibitors: Europe
- Importance of Nonclinical Factors to Prescribing Decisions in Severe Hemophilia A Without Inhibitors: United States
- Importance of Nonclinical Factors to Prescribing Decisions in Severe Hemophilia A Without Inhibitors: Europe
- Key Findings: Stated vs. Derived Importance
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Severe Hemophilia A Without Inhibitors: United States
- Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Severe Hemophilia A Without Inhibitors: Europe
- Product Performance Against Treatment Drivers and Goals
- Key Findings
- Overall Performance of Key Therapies for Severe Hemophilia A Without Inhibitors: United States
- Overall Performance of Key Therapies for Severe Hemophilia A Without Inhibitors: Europe
- Mean Overall Performance of Key Therapies for Severe Hemophilia A Without Inhibitors: United States and Europe
- Relative Performance of Key Therapies for Severe Hemophilia A Without Inhibitors Across Select Efficacy Attributes: United States
- Relative Performance of Key Therapies for Severe Hemophilia A Without Inhibitors Across Select Efficacy Attributes: Europe
- Relative Performance of Key Therapies for Severe Hemophilia A Without Inhibitors Across Select Safety and Tolerability Attributes: United States
- Relative Performance of Key Therapies for Severe Hemophilia A Without Inhibitors Across Select Safety and Tolerability Attributes: Europe
- Relative Performance of Key Therapies for Severe Hemophilia A Without Inhibitors Across Select Convenience of Administration Attributes: United States
- Relative Performance of Key Therapies for Severe Hemophilia A Without Inhibitors Across Select Convenience of Administration Attributes: Europe
- Relative Performance of Key Therapies for Severe Hemophilia A Without Inhibitors Across Select Nonclinical Attributes: United States
- Relative Performance of Key Therapies for Severe Hemophilia A Without Inhibitors Across Select Nonclinical Attributes: Europe
- Assessment of Unmet Need
- Key Findings: Unmet Need in Severe Hemophilia A Without Inhibitors
- Surveyed Hematologistsu2019 Satisfaction with the Performance of Key Therapies for Severe Hemophilia A Without Inhibitors on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
- Surveyed Hematologistsu2019 Satisfaction with the Performance of Key Therapies for Severe Hemophilia A Without Inhibitors on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
- Surveyed Hematologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Severe Hemophilia A Without Inhibitors: United States
- Surveyed Hematologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Severe Hemophilia A Without Inhibitors: Europe
- Surveyed Hematologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Severe Hemophilia A Without Inhibitors: United States
- Surveyed Hematologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Severe Hemophilia A Without Inhibitors: Europe
- Surveyed Hematologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Severe Hemophilia A Without Inhibitors: United States
- Surveyed Hematologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Severe Hemophilia A Without Inhibitors: Europe
- Surveyed Hematologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Severe Hemophilia A Without Inhibitors: United States
- Surveyed Hematologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Severe Hemophilia A Without Inhibitors: Europe
- Key Findings: Unmet Need in Severe Hemophilia A Without Inhibitors and Related Indications
- Surveyed Hematologists' Ascribed Level of Unmet Need in Severe Hemophilia A Without Inhibitors and Related Indications: United States
- Surveyed Hematologists' Ascribed Level of Unmet Need in Severe Hemophilia A Without Inhibitors and Related Indications: Europe
- Opportunity Analysis
- Target Product Profiles
- Appendix
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is…
